Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2019

Revenue Recognition

Schedule of disaggregation of revenue by test families

	Three months ended
	March 31,
	2019		2018
(Amounts in thousands)
Sales of genetic tests
Panorama NIPT	$	37,246	$	33,267
HCS		22,749		18,262
Other genetic tests		3,369		2,740
Product revenues		63,364		54,269
Licensing and other
Constellation		1,332		1,305
Qiagen		148		5,500
Other		1,980		1,266
Licensing and other revenues		3,460		8,071
Total revenues	$	66,824	$	62,340

Schedule of disaggregation of revenue by payer types

	Three months ended
	March 31,
	2019		2018
(Amounts in thousands)
Insurance carriers	$	50,201	$	44,142
Laboratory partners		10,023		14,888
Patients		6,600		3,310
Total revenues	$	66,824	$	62,340

Schedule of total revenue by geographic area

	Three months ended
	March 31,
	2019		2018
(Amounts in thousands)
United States	$	60,283	$	50,364
Americas, excluding U.S.		818		850
Europe, Middle East, India, Africa		4,004		9,322
Other		1,719		1,804
Total revenues	$	66,824	$	62,340

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at		Balance at
	March 31,		December 31,
(Amounts in thousands)	2019		2018
Assets:
Accounts receivable	$	60,293	$	62,223
Liabilities:
Deferred revenue, current portion	$	4,928	$	4,131
Deferred revenue, long-term portion		39,698		40,058
Total deferred revenues	$	44,626	$	44,189

Schedule of changes in the balance of deferred revenues

	Deferred
	Revenues
	(in thousands)
Balance at December 31, 2018	$	44,189
Increase in deferred revenues		2,422
Revenue recognized during the period that was included in deferred revenues at the beginning of the period		(492)
Revenue recognized from performance obligations satisfied within the same period		(1,493)
Balance at March 31, 2019	$	44,626